Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 9 November 2026.
Announcements
6,267
Total raised
£165B
disclosed amounts
This month
£206M
raised so far
The funding follows a previous loan in 2022 and will support international growth, product development and marketing.
"We’re a small business with sport in our DNA and we’re focussed on doing one thing well – making the world’s greatest sport tapes. We have now sold over five million meters of our flagship kinesiology tape and we’re teaching techniques and skills to athletes all over the world to master faster and more effective tape applications."
The investment round was co-led by Venrex and Redrice Ventures to support platform expansion.
"Lovetovisit has gone from strength to strength this year and we’re incredibly proud to have such esteemed investors on board. Building the business and hitting these milestones alongside my sister is a dream. We each bring unique strengths to the team, but we share a passion for supporting the many amazing events, attractions and experiences in the UK to digitise and scale. There are so many weird, wonderful and iconic things to do in this country, we just need to make it easier for people to find, explore and book them. Our goal is to be the go-to platform for booking memorable things to do and this raise is a big step towards achieving that mission."
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."
The investment round was led by New York-based Coefficient Capital with participation from multiple venture firms.
"The way ZOE combines their own science and data to drive huge shifts in consumer behavior towards health immediately impressed us"
Guinness Ventures led the Series B round alongside participants including Scottish Enterprise, Growthdeck, and Virgin Money.
"This investment accelerates our mission to delivergame improvement technology to 60 million golfers around the world. Throughout 2024 we plan to invest in infrastructure across the USA to support our retail and distribution partners. Golfers globally love our GPS, rangefinder and shot tracking technology, having sold products in 160 different countries worldwide in 2023. Golf has experienced a huge change in the past 5 years, people of all ages and demographics love the sport. With Shot Scope golfers can improve quickly and enjoy the game they love even more."
